Stereospecific inhibition of CETP by chiral N,N-disubstituted trifluoro-3-amino-2-propanols.
Chiral N,N-disubstituted trifluoro-3-amino-2-propanols represent a recently discovered class of compounds that inhibit the neutral lipid transfer activity of cholesteryl ester transfer protein (CETP). These compounds all contain a single chiral center that is essential for inhibitory activity. (R,S)SC-744, which is composed of a mixture of the two enantiomers, inhibits CETP-mediated transfer of [(3)H]cholesteryl ester ([(3)H]CE) from HDL donor particles to LDL acceptor particles with an IC(50) = 200 nM when assayed using a reconstituted system in buffer and with an IC(50) = 6 microM when assayed in plasma. Upon isolation of the enantiomers, it was found that the (R,+) enantiomer, SC-795, was about 10-fold more potent than the mixture, and that the (S,-) enantiomer, SC-794, did not have significant inhibitory activity (IC(50) > 0.8 microM). All of the activity of the (S,-)SC-794 enantiomer could be accounted for by contamination of this sample with a residual 2% of the highly potent (R,+) enantiomer, SC-795. The IC(50) of (R,+)SC-795, 20 nM, approached the concentration of CETP (8 nM) in the buffer assay. These chiral N,N-disubstituted trifluoro-3-amino-2-propanols were found to associate with both LDL and HDL, but did not disrupt overall lipoprotein structure. They did not affect the on or off rates of CETP binding to HDL disk particles. Inhibition was highly specific since the activities of phospholipid transfer protein and lecithin cholesterol acyl transferase were not affected. Competition experiments showed that the more potent enantiomer (R)SC-795 prevented cholesteryl ester binding to CETP, and direct binding experiments demonstrated that this inhibitor bound to CETP with high affinity and specificity. It is estimated, based on the relative concentrations of inhibitor and lipid in the transfer assay, that (R)SC-795 binds approximately 5000-fold more efficiently to CETP than the natural ligand, cholesteryl ester. We conclude that these chiral N,N-disubstituted trifluoro-3-amino-2-propanol compounds do not affect lipoprotein structure or CETP-lipoprotein recognition, but inhibit lipid transfer by binding to CETP reversibly and stereospecifically at a site that competes with neutral lipid binding.
Connolly
D T
DT
Pharmacia Discovery Research, 800 North Lindbergh Boulevard, St. Louis, Missouri 63167, USA. Daniel.T.Connelly@monsanto.com
Witherbee
B J
BJ
Melton
M A
MA
Durley
R C
RC
Grapperhaus
M L
ML
McKinnis
B R
BR
Vernier
W F
WF
Babler
M A
MA
Shieh
J J
JJ
Smith
M E
ME
Sikorski
J A
JA
D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D016466:CHO Cells; D002352:Carrier Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D053480:Cholesterol Ester Transfer Proteins; D002788:Cholesterol Esters / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006224:Cricetinae; D004220:Disulfides / Q000737:chemistry / Q000494:pharmacology; D004357:Drug Synergism; D004587:Electrophoresis, Agar Gel; D006023:Glycoproteins; D006801:Humans; D008075:Lipoproteins, HDL / Q000037:antagonists & inhibitors / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000037:antagonists & inhibitors / Q000378:metabolism; D008565:Membrane Proteins / Q000037:antagonists & inhibitors; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000378:metabolism; D049294:Phospholipid Transfer Proteins; D010743:Phospholipids / Q000037:antagonists & inhibitors; D011412:Propanolamines / Q000737:chemistry / Q000494:pharmacology*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D013997:Time Factors; D014280:Triglycerides / Q000037:antagonists & inhibitors*
C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D002788:Cholesterol Esters; D004220:Disulfides; D006023:Glycoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008565:Membrane Proteins; D049294:Phospholipid Transfer Proteins; D010743:Phospholipids; D011412:Propanolamines; D014280:Triglycerides; D007862:Phosphatidylcholine-Sterol O-Acyltransferase